Kyverna Therapeutics (KYTX) Interest Coverage Ratio (2023 - 2026)
Kyverna Therapeutics' (KYTX) quarterly Interest Coverage Ratio came in at 1.18 in Q1 2026, up 97.61% YoY from 0.6 in Q1 2025, and up 98.94% on a QoQ basis from 110.65 in Q4 2025.
Kyverna Therapeutics (KYTX) Interest Coverage Ratio (2023 - 2026) Analysis & Trends
Kyverna Therapeutics (KYTX) has 4 years of Interest Coverage Ratio data on file, last reported at 1.18 in Q1 2026.
- Quarterly Interest Coverage Ratio rose 97.61% year-over-year to 1.18 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 4.66 (up 86.73% YoY) and the FY2025 annual result came in at 3.88, up 91.65% from the prior year.
- Interest Coverage Ratio climbed to 1.18 in Q1 2026, from 110.65 in the prior quarter.
- In the past five years, Interest Coverage Ratio ranged from a high of 1.18 in Q1 2026 to a low of 454.83 in Q4 2023.
- A 4-year average of 57.34 and a median of 20.26 in 2023 frame the typical range for Interest Coverage Ratio.
- Annual changes were most pronounced in 2025 — Interest Coverage Ratio sank 697.53% — and 2026, when it soared 97.61%.
- Tracing KYTX's Interest Coverage Ratio over 4 years: stood at 454.83 in 2023, then jumped by 96.95% to 13.87 in 2024, then slumped by 697.53% to 110.65 in 2025, then jumped by 98.94% to 1.18 in 2026.
- The last three Interest Coverage Ratio figures came in at 1.18 (Q1 2026), 110.65 (Q4 2025), and 2.4 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Interest Cover (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 2.84 |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 24.64 |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -0.19 |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 8.18 |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -0.01 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 0.61 |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 2.82 |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -0.08 |
| 10 | Kyverna Therapeutics | 505.26 Mn | 505.26 Mn | - | -1.21 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -1.21 |
| Mar 31, 2026 | -1.18 |
| Dec 31, 2025 | -110.65 |
| Sep 30, 2025 | -2.40 |
| Jun 30, 2025 | -20.55 |
| Mar 31, 2025 | -49.23 |
| Dec 31, 2024 | -13.87 |
| Sep 30, 2024 | -4.37 |
| Jun 30, 2024 | -2.65 |
| Mar 31, 2024 | -16.33 |
| Dec 31, 2023 | -454.83 |
| Sep 30, 2023 | -27.05 |
| Jun 30, 2023 | -22.10 |
| Mar 31, 2023 | -20.26 |